Avila- Sanofi Aventis deal includes AVL-292 a BTK inhibitor

[Guest guest]

AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine

kinase (Btk).

It works on the same target as PCI-32765 in CLL .

The first clinical study of AVL-292, which is being conducted in the U.S., is a

double-blind, placebo-controlled, single ascending dose study and will evaluate

the safety, tolerability, and pharmacokinetic profile of AVL-292 in healthy

volunteers.

~chris